Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
Eligible subjects will receive open-label AXS-07 for up to 8 weeks for at-home treatment of their next 4 migraine attacks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has an established diagnosis of migraine with or without aura
Has experienced an inadequate response to oral CGRP inhibitors for the acute treatment of migraine
You may not be if
Pregnant, breastfeeding, or planning to become pregnant during the study
Has previously received any investigational drug or device or investigational therapy within 30 days before Screening
Clareo Health | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
